Michelle A Worthington1, David J Miklowitz2, Mary O'Brien1, Jean Addington3, Carrie E Bearden4, Kristin S Cadenhead5, Barbara A Cornblatt6, Daniel H Mathalon7, Thomas H McGlashan8, Diana O Perkins9, Larry J Seidman10,11, Ming T Tsuang5, Elaine F Walker12, Scott W Woods8, Tyrone D Cannon1,8. 1. Department of Psychology, Yale University, New Haven, Connecticut. 2. Department of Psychiatry, UCLA Semel Institute, University of California, Los Angeles, California. 3. Department of Psychiatry, Hotchkiss Brain Institute, Calgary, Alberta, Canada. 4. Department of Psychiatry and Biobehavioral Sciences and Psychology, UCLA, Los Angeles, California. 5. Department of Psychiatry, UCSD, San Diego, California. 6. Department of Psychiatry, Zucker Hillside Hospital, Long Island, New York. 7. Department of Psychiatry, UCSF, and SFVA Medical Center, San Francisco, California. 8. Department of Psychiatry, Yale University, New Haven, Connecticut. 9. Department of Psychiatry, University of North Carolina, Chapel Hill, North Carolina. 10. Department of Psychiatry, Harvard Medical School at Beth Israel Deaconess Medical Center, Boston, Massachusetts. 11. Massachusetts General Hospital, Boston, Massachusetts. 12. Department of Psychology and Psychiatry, Emory University, Atlanta, Georgia.
Abstract
AIM: Recent findings suggest that family-focused therapy (FFT) is effective for individuals at clinical high-risk for psychosis (CHR-P). As outcomes of CHR-P individuals are quite varied, certain psychosocial interventions may be differentially effective in subgroups. The present study examined change in positive symptoms for CHR-P individuals at different levels of predicted risk for conversion to psychosis who received either FFT, a brief form of family education termed enhanced care (EC) or treatment as usual. METHODS: Participants were drawn from the North American Prodromal Longitudinal Study (NAPLS2). A subset of NAPLS2 participants completed a randomized study involving FFT or EC. The present study includes participants from the FFT-CHR sub-study and non-randomized NAPLS2 participants. Predicted risk of conversion was calculated using the Individualized Risk Calculator for Psychosis. Robust linear regressions evaluated whether the association between predicted risk of conversion and positive symptom change differed across intervention groups. RESULTS: A total of 94 participants from the FFT-CHR sub-study (FFT-CHR n = 50, EC n = 44) and 401 non-randomized NAPLS2 participants were included in this study. There was a treatment group by predicted risk of conversion interaction that predicted positive symptom improvement: higher risk individuals improved more with FFT-CHR than EC or the non-randomized NAPLS group, whereas lower-risk individuals did not differ in positive symptom improvement across treatment groups (FFT-CHR vs EC: P = .03, β = 20.27; FFT-CHR vs NAPLS2: P < .001, β = 28.40). CONCLUSIONS: Intensive treatments such as FFT-CHR may be most appropriate for individuals at the highest levels of clinical risk for psychosis.
AIM: Recent findings suggest that family-focused therapy (FFT) is effective for individuals at clinical high-risk for psychosis (CHR-P). As outcomes of CHR-P individuals are quite varied, certain psychosocial interventions may be differentially effective in subgroups. The present study examined change in positive symptoms for CHR-P individuals at different levels of predicted risk for conversion to psychosis who received either FFT, a brief form of family education termed enhanced care (EC) or treatment as usual. METHODS: Participants were drawn from the North American Prodromal Longitudinal Study (NAPLS2). A subset of NAPLS2 participants completed a randomized study involving FFT or EC. The present study includes participants from the FFT-CHR sub-study and non-randomized NAPLS2 participants. Predicted risk of conversion was calculated using the Individualized Risk Calculator for Psychosis. Robust linear regressions evaluated whether the association between predicted risk of conversion and positive symptom change differed across intervention groups. RESULTS: A total of 94 participants from the FFT-CHR sub-study (FFT-CHR n = 50, EC n = 44) and 401 non-randomized NAPLS2 participants were included in this study. There was a treatment group by predicted risk of conversion interaction that predicted positive symptom improvement: higher risk individuals improved more with FFT-CHR than EC or the non-randomized NAPLS group, whereas lower-risk individuals did not differ in positive symptom improvement across treatment groups (FFT-CHR vs EC: P = .03, β = 20.27; FFT-CHR vs NAPLS2: P < .001, β = 28.40). CONCLUSIONS: Intensive treatments such as FFT-CHR may be most appropriate for individuals at the highest levels of clinical risk for psychosis.
Authors: Jean Addington; Kristin S Cadenhead; Tyrone D Cannon; Barbara Cornblatt; Thomas H McGlashan; Diana O Perkins; Larry J Seidman; Ming Tsuang; Elaine F Walker; Scott W Woods; Robert Heinssen Journal: Schizophr Bull Date: 2007-01-25 Impact factor: 9.306
Authors: S M Francey; B Nelson; A Thompson; A G Parker; M Kerr; C Macneil; R Fraser; F Hughes; K Crisp; S Harrigan; S J Wood; M Berk; P D McGorry Journal: Schizophr Res Date: 2010-03-26 Impact factor: 4.939
Authors: David J Miklowitz; David A Axelson; Boris Birmaher; Elizabeth L George; Dawn O Taylor; Christopher D Schneck; Carol A Beresford; L Miriam Dickinson; W Edward Craighead; David A Brent Journal: Arch Gen Psychiatry Date: 2008-09
Authors: Ricardo E Carrión; Barbara A Cornblatt; Cynthia Z Burton; Ivy F Tso; Andrea M Auther; Steven Adelsheim; Roderick Calkins; Cameron S Carter; Tara Niendam; Tamara G Sale; Stephan F Taylor; William R McFarlane Journal: Am J Psychiatry Date: 2016-07-01 Impact factor: 18.112
Authors: Tyrone D Cannon; Changhong Yu; Jean Addington; Carrie E Bearden; Kristin S Cadenhead; Barbara A Cornblatt; Robert Heinssen; Clark D Jeffries; Daniel H Mathalon; Thomas H McGlashan; Diana O Perkins; Larry J Seidman; Ming T Tsuang; Elaine F Walker; Scott W Woods; Michael W Kattan Journal: Am J Psychiatry Date: 2016-07-01 Impact factor: 18.112
Authors: Tyrone D Cannon; Kristin Cadenhead; Barbara Cornblatt; Scott W Woods; Jean Addington; Elaine Walker; Larry J Seidman; Diana Perkins; Ming Tsuang; Thomas McGlashan; Robert Heinssen Journal: Arch Gen Psychiatry Date: 2008-01
Authors: Elizabeth Thompson; Pamela Rakhshan; Steven C Pitts; Caroline Demro; Zachary B Millman; Kristin Bussell; Jordan DeVylder; Emily Kline; Gloria M Reeves; Jason Schiffman Journal: Schizophr Res Date: 2018-09-08 Impact factor: 4.939
Authors: Christoph U Correll; Britta Galling; Aditya Pawar; Anastasia Krivko; Chiara Bonetto; Mirella Ruggeri; Thomas J Craig; Merete Nordentoft; Vinod H Srihari; Sinan Guloksuz; Christy L M Hui; Eric Y H Chen; Marcelo Valencia; Francisco Juarez; Delbert G Robinson; Nina R Schooler; Mary F Brunette; Kim T Mueser; Robert A Rosenheck; Patricia Marcy; Jean Addington; Sue E Estroff; James Robinson; David Penn; Joanne B Severe; John M Kane Journal: JAMA Psychiatry Date: 2018-06-01 Impact factor: 21.596
Authors: David J Miklowitz; Jean M Addington; Mary P O'Brien; Danielle M Denenny; Marc J Weintraub; Jamie L Zinberg; Daniel H Mathalon; Barbara A Cornblatt; Michelle S Friedman-Yakoobian; William S Stone; Kristin S Cadenhead; Scott W Woods; Catherine A Sugar; Tyrone D Cannon; Carrie E Bearden Journal: Early Interv Psychiatry Date: 2021-08-23 Impact factor: 2.721